Professional Publications

Pospisilova, H.; Baens, M.; Michaux, L.; Stul, M.; Van Hummelen, P.; Van Loo, P.; Vermeesch, J.; Jarosova, M.; Zemanova, Z.; Michalova, K.; Van den Berghe, I.; Alexander, H.D.; Hagemeijer, A.; Vandenberghe, P.; Cools, J.; De Wolf-Peeters, C.; Marynen, P.; Wlodarska, I.

Interstitial del(14)(q) involving IGH : a novel recurrent aberration in B-NHL

[year of publication 2008, impact factor 6.924]

Čmejla, R.; Čmejlová, J.; Handrková, H.; Petrák, J.; Petrtýlová, K.; Mihál, V.; Starý, J.; Černá, Z.; Jabali, Y.; Pospíšilová, D.

Identification of mutations in the ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) genes in Czech patients with Diamond-Blackfan anemia

[year of publication 2008, impact factor 6.887]

Toracchio, S.; Foyle, A.; Sroller, V.; Reed, J.A.; Wu, J.; Kozinetz, C.A.; Butel, J.S.

Lymphotropism of Merkel cell polyomavirus infection, Nova Scotia, Canada

[year of publication 2011, impact factor 6.859]

Gillett, C.; Fantl, V.; Smith, R.; Fisher, Ch.; Bartek, J.; Dickson, C.; Barnes, D.; Peters, G.

Amplification and overexpression of cyclin-D1 in breast cancer detected by immunohistochemical staining

[year of publication 2006, impact factor 6.822]

Motovska, Z.; Widimsky, P.; Petr, R.; Bilkova, D.; Marinov, I.; Simek, S.; Kala, P.

Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness

[year of publication 2010, impact factor 6.802]

Pastva, O.; Chrastinova, L.; Bockova, M.; Kotlin, R.; Suttnar, J.; Hlavackova, A.; Stikarova, J.; Ceznerova, E.; Cermak, J.; Homola, J.; Dyr, J.E.

Hsp70 trap assay for detection of misfolded subproteome related to myelodysplastic syndromes

[year of publication 2019, impact factor 6.785 ]

Garelius, H.K.; Johnston, W.T.; Smith, A.G.; Park, S.; de Swart, L.; Fenaux, P.; Symeonidis, A.; Sanz, G.; Čermák, J.; Stauder, R.; Malcovati, L.; Mittelman, M.; van de Loosdrecht, A.A.; van Marrewijk, C.J.; Bowen, D.; Crouch, S.; de Witte, T.J.; Hellström-Lindberg, E.

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome

[year of publication 2016, impact factor 6.754 ]

Sahr, K.E.; Coetzer, T.L.; Moy, L.S.; Derick, L.H.; Chishti, A.H.; Jarolim, P.; Lorenzo, F.; del Giudice, E.M.; Iolascon, A.; Gallanello, R.; Cao, A.; Delaunay, J.; Liu, S.H.; Palek, J.

Spectrin Cagliari : an ALA->Gly substitution in helix 1 of beta spectrin repeat 17 that severely disrupts the structure and self-association of the erythrocyte spectrin heterodimer

[year of publication 2006, impact factor 6.733]

Kaštánková, I.; Štach, M.; Žižková, H.; Ptáčková, P.; Šmilauerová, K.; Mucha, M.; Šroller, V.; Otáhal, P.

Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells

[year of publication 2022, impact factor 6.698 ]

Stojkov, K.; Silzle, T.; Stussi, G.; Schwappach, D.; Bernhard, J.; Bowen, D.; Čermák, J.; et al.

Guideline-based indicators for adult patients with myelodysplastic syndromes

[year of publication 2020, impact factor 6.686 ]

Oster, H.S.; Crouch, S.; Smith, A.; Yu, G.; Shrkihe, B.A.; Baruch, S.; Kolomansky, A.; Ben-Ezra, J.; Naor, S.; Fenaux, P.; Symeonidis, A.; Stauder, R.; Cermak, J.; et al.

A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS

[year of publication 2021, impact factor 6.686 ]

Szikszai, K.; Krejcik, Z.; Klema, J.; Loudova, N.; Hrustincova, A.; Belickova, M.; Hruba, M.; Vesela, J.; Stranecky, V.; Kundrat, D.; Pecherkova, P.; Cermak, J.; Jonasova, A.; Dostalova Merkerova, M.

LncRNA profiling reveals that the deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 is associated with higher-risk myelodysplastic syndrome

[year of publication 2020, impact factor 6.639 ]

Koralkova, P.; Belickova, M.; Kundrat, D.; Dostalova Merkerova, M.; Krejcik, Z.; Szikszai, K.; Kaisrlikova, M.; Vesela, J.; Vyhlidalova, P.; Stetka, J.; Hlavackova, A.; Suttnar, J.; Flodr, P.; Stritesky, J.; Jonasova, A.; Cermak, J.; Divoky, V.

Low plasma citrate levels and specific transcriptional signatures associated with quiescence of CD34+ progenitors predict Azacitidine therapy failure in MDS/AML patients

[year of publication 2021, impact factor 6.639 ]

Tillmann, S.; Olschok, K.; Schroder, S.K.; Butow, M.; Baumeister, J.; Kalmer, M.; Preussger, V.; Weinbergerova, B.; Kricheldorf, K.; Mayer, J.; Kubesova, B.; Racil, Z.; et al.

The unfolded protein response is a major driver of LCN2 expression in BCR-ABL- and JAK2V617F-positive MPN

[year of publication 2021, impact factor 6.639 ]

Holoubek, A.; Strachotová, D.; Otevřelová, P.; Röselová, P.; Heřman, P.; Brodská, B.

AML-related NPM mutations drive p53 delocalization into the cytoplasm with possible impact on p53-dependent stress response

[year of publication 2021, impact factor 6.639 ]

Krsmanovic, P.; Mocikova, H.; Chramostova, K.; Klanova, M.; Trnkova, M.; Pesta, M.; Laslo, P.; Pytlik, R.; et al.

Circulating microRNAs in cerebrospinal fluid and plasma: sensitive tool for detection of secondary CNS involvement, monitoring of therapy and prediction of CNS relapse in aggressive B-NHL lymphomas

[year of publication 2022, impact factor 6.639 ]

Bártek, J.; Vojtěšek, B.; Grand, R.J.; Gallimore, P.H.; Lane, D.P.

Cellular localization and T antigen binding of the retinoblastoma protein

[year of publication 2006, impact factor 6.634]

Eeles, R.A.; Warren, W.; Knee, G.; Bartek, J.; Averill, D.; Stratton, M.R.; Blake, P.R.; Tait, D.M.; Lane, D.P.; Easton, D.F.; Yarnold, J.R.; Cooper, C.S.; Sloane, J.P.

Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours : molecular and immunohistochemical findings

[year of publication 2006, impact factor 6.634]

Boeckx, N.; Jansen, M.W.J.C.; Haskovec, C.; Vandenberghe, P.; van der Velden, V.H.J.; van Dongen, J.J.M.:

Identification of e 19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligation-mediated PCR.

[year of publication 2006, impact factor 6.612]

Zwierzina, H.; Suciu, S.; Loeffler-Ragg, J.; Neuwirtova, R.; Fenaux, P.; Beksac, M.; Harousseau, J.; Nuessler, V.; Cermak, J.; Solbu, G.; Willemze, R.; De Witte, T.; Amadori, S.

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia

[year of publication 2008, impact factor 6.612]